Guangdong Marubi Biotechnology (603983.SS) Earnings Analysis

Guangdong Marubi Biotechnology (603983.SS) next reports earnings on 2026-08-29, consensus EPS 0.1791 CNY. Last quarter (2026-04-30) it missed with EPS 0.251 CNY vs 0.2519 CNY est (-0.4%). It has beaten estimates in 1/6 recent quarters (17%). Trailing P/E 58.05.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 603983.SS next report earnings?

Next earnings date2026-08-29
Consensus EPS estimate0.1791 CNY
Revenue estimate0.98B

603983.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-300.251 CNY0.2519 CNY-0.4%Miss
2026-04-010.00917 CNY0.3614 CNY-97.5%Miss
2025-10-300.145 CNY0.1577 CNY-8.1%Miss
2025-04-250.25 CNY0.24 CNY+4.2%Beat
2025-03-310.34 CNYn/an/an/a
2024-10-250.16 CNY0.19 CNY-15.8%Miss
2024-08-230.16 CNY0.23 CNY-30.4%Miss

Beat rate: 1/6 (17%) over reported quarters with consensus data.

603983.SS valuation and analyst view

Trailing P/E58.05
Trailing EPS0.53171 CNY
Price / book3.58
Dividend yield1.63%
Market cap12.10B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Guangdong Marubi Biotechnology (603983.SS)'s next earnings date?

Guangdong Marubi Biotechnology is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.1791 CNY and revenue estimate of 0.98B.

Did 603983.SS beat earnings last quarter?

In its 2026-04-30 report, 603983.SS posted EPS of 0.251 CNY versus a 0.2519 CNY estimate — a miss of 0.4%.

What is 603983.SS's earnings track record?

Over the last 6 reported quarters with consensus data, 603983.SS beat estimates 1 times (17%).

What is 603983.SS's current P/E ratio and EPS?

603983.SS trades at a trailing P/E of 58.05 on trailing EPS of 0.5317057655860349 CNY.

What do analysts rate 603983.SS?

603983.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.